Parafoveal retinal vessel density assessment by OCTA in healthy eyes

News
Article

Study aims to identify methodology for least amount of variation, greatest test-retest reliability

(FIGURE 2) Registration of consecutive scans of a normal eye imaged on the Plex. A1-A3: Full retinal thickness 3x3 mm OCTA scans. B: Registered OCTA image generated by the averaging of A1-A3 scans.

Plex imaging OCTA device

(FIGURE 1) Scans of a normal eye imaged on the Plex OCTA device. (A) Superficial capillary plexus, (B) Deep capillary plexus, (C) Full retinal layer. A1-C1: 3 x 3 mm en face images. A2-C2: Binary images used to calculate VAD. A3-C3: Skeletonized images of corresponding binary images used to calculate VSD.

Plex imaging OCTA device

(FIGURE 3) Mean VSD measurements across three OCTA devices following registration of images at various retinal layers. (A) Superfi cial capillary plexus, (B) Deep capillary plexus, (C) Full retinal layer. The devices are all signifi cantly different in vessel density measurements. All p-values were less than 0.0001 (**). (Figures courtesy of Malvika Arya, BS)

 

EDITOR’S NOTE
Ophthalmology Times is pleased to announce Malvika Arya, BS, OCT research fellow, New England Eye Center, Tufts Medical Center, Boston, as the third-place honoree of the inaugural Ophthalmology Times Research Scholar Honoree Program. Arya’s abstract is featured here. The Ophthalmology Times Research Scholar Honoree Program is dedicated to the education of retina fellows and residents by providing a unique opportunity for fellows/ residents to share notable research and challenging cases with their peers and mentors. The program is supported by unrestricted grants from Regeneron Pharmaceuticals and Carl Zeiss Meditec Inc. Look for more case study honorees in future issues of Ophthalmology Times. For more details about the Research Scholar Honoree program, go to OphthalmologyTimes.com/2017RSH

Purpose

Various methods for parafoveal vessel density (VD) assessment have been reported in the literature. The purpose of this study was:

  • to assess the variability in VD measurements across three commercially available optical coherence tomography angiography (OCTA) devices,

  • to identify a methodology that offers the least amount of variation and the greatest test-retest reliability of VD, and

  • to assess the effect of registration of consecutive scans on VD variability.

Methods

Fifteen eyes of eight healthy individuals were imaged thrice consecutively on the Optovue RTVue XR Avanti (Avanti), Zeiss Cirrus HDOCT 5000 (Cirrus), and Zeiss PLEX Elite 9000 (Plex) OCTA devices. Scans of 3 x 3 mm centered at the fovea were obtained, and automated segmentations at the levels of the superficial capillary plexus (SCP), deep capillary plexus (DCP), and full retina were generated.

To measure vessel area density (VAD), two automated local thresholding techniques, the Mean method and the Otsu method, were applied to en face images to binarize them, using ImageJ (National Institutes of Health, Bethesda, MD) software. Any signal above their respective thresholds was interpreted as flow. VAD was calculated as the percentage of area representing flow divided by the total scanned area.

Binary images were then converted to skeletonized images, where vessels were reduced to a width of one pixel. Skeletonized images were used to calculate vessel skeleton density (VSD) as the ratio of the total skeleton area over the total scanned area. Figure 1 represents en face binarized and skeletonized images at the level of the SCP, DCP, and full retina obtained on the Plex.

The coefficient of repeatability (CoR) for each VAD and VSD method and for each segmentation was calculated to assess the reproducibility of images of the same device on repeat scanning, and of VAD and VSD by different devices. A lower CoR value indicated a tighter dispersion of data and higher reproducibility.

For each eye, three consecutive repeat scans obtained on each OCTA device were registered and the signal was averaged to generate one registered OCTA image (Figure 2).

Registration and averaging was performed separately for each of the three retinal layers and analyzed for comparability across all three devices.

Results

The CoR values showed that the Mean VSD method provided more precise VD measurements, suggesting that skeletonized images by this method offer greater repeatability in consecutive scans on each device. The images obtained by the Plex OCTA device were more closely reproducible as compared with the other two devices, irrespective of retinal layer imaged.

For the original, unregistered images of various retinal layers, all three OCTA devices were significantly different from each other (p < 0.0001 for each).

Figure 3 highlights Mean VSD measurements following the registration of images of various retinal layers across all three OCTA devices. All devices were again significantly different from each other (p < 0.0001 for each).

The reproducibility of Mean VSD measurement in unregistered images of each retinal layer obtained on each device separately was fairly similar, although the DCP seemed superior with lower CoR values.

Following the registration of images, Mean VSD was significantly different from the unregistered images for each device and plexus (p < 0.05 for each). Further analysis revealed that after registration, Mean VSD remained within 1% of the Mean VSD value of a single scan.

Conclusion

Currently available OCTA devices show significant variability in their parafoveal VD assessment for a normal subject.

The Plex, a swept-source OCTA device, demonstrated the highest intra-session repeatability. This may be because its faster scanning speeds allow for more dense scanning in comparable times, allowing for better image quality.

The Mean VSD methodology provides a more repeatable assessment of parafoveal VD across the three OCTA devices for the same patient.

Mean VSD measurement after registration of scans was significantly different than that of unregistered scans for each plexus on each device.

However, numerically, the differences noted were small with Mean VSD remaining within 1% of a single volumetric scan, for which clinical significance remains to be determined.

Due to the observed inter-device variability, caution is advised when comparing quantitative analyses across different OCTA devices.

Disclosures:

Malvika Arya, BS1,2
E: malvika.arya@tufts.edu

A. Yasin Alibhai, MD1
E: yasin.alibhai@gmail.com

Carl B. Rebhun, BA1,2
E: Carl.rebhun@gmail.com

Xuejing Chen, MD1
E: xuejingchen3@gmail.com

Elias Reichel, MD1
E: ereichel@tuftsmedicalcenter.org

Caroline R. Baumal, MD1
E: cbaumal@tuftsmedicalcenter.org

Andre J. Witkin, MD1
E: AJWitkin@Gmail.com

Jay S. Duker, MD1
E: jduker@tuftsmedicalcenter.org
Dr. Duker receives research support from Carl Zeiss Meditec, Optovue, and Topcon.

Nadia K. Waheed, MD, MPH1

E: nadiakwaheed@gmail.com
Dr. Waheed is a consultant for Optovue, and receives research support from Carl Zeiss Meditec and Topcon.

There are no conflicting relationships for any other author. 1 New England Eye Center, Tufts Medical Center, Boston. 2 Department of Electrical Engineering and Computer Science, and Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, MA.

Recent Videos
WIO 2024: An educator's perspective on shattering glass ceilings in ophthalmology
Hannah Chiu, MD, FRCSC, highlights some of the early benefits of an AI-operated telephone call system for postoperative patient care at WIO 2024
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Understanding fluid dynamics in wet macular degeneration
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
© 2024 MJH Life Sciences

All rights reserved.